These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 31372015)

  • 1. Cost-benefit comparison of liraglutide and sitagliptin in the treatment of type 2 diabetes in Thailand.
    Deerochanawong C; Kosachunhanun N; Gadekar AV; Chotikanokrat P; Permsuwan U
    Clinicoecon Outcomes Res; 2019; 11():423-430. PubMed ID: 31372015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis.
    Barnett AH; Arnoldini S; Hunt B; Subramanian G; Hoxer CS
    Diabetes Obes Metab; 2018 Aug; 20(8):1921-1927. PubMed ID: 29652101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liraglutide Versus Sitagliptin in a 24-week, Multicenter, Open-label, Randomized, Parallel-group Study in Japanese Type 2 Diabetes Mellitus Patients Responding Inadequately to a Sulfonylurea and/or One or Two Other Oral Antidiabetic Drugs (JDDM 33).
    Yokoyama H; Hirao K; Yamaguchi K; Oishi M; Lee G; Yagi N; Takamura H; Kashiwagi A
    Jpn Clin Med; 2014; 5():33-41. PubMed ID: 25288908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Clinical Effectiveness and Cost Savings of Liraglutide Versus Sitagliptin in Treating Type 2 Diabetes for 1 and 2 Years.
    Li Q; Ganguly R; Ganz ML; Gamble C; Dang-Tan T
    Diabetes Ther; 2018 Jun; 9(3):1279-1293. PubMed ID: 29744818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.
    Lee WC; Samyshkin Y; Langer J; Palmer JL
    J Med Econ; 2012; 15 Suppl 2():28-37. PubMed ID: 22834986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme.
    Bain SC; Hansen BB; Malkin SJP; Nuhoho S; Valentine WJ; Chubb B; Hunt B; Capehorn M
    Diabetes Ther; 2020 Jan; 11(1):259-277. PubMed ID: 31833042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world clinical and economic outcomes of liraglutide versus sitagliptin in patients with type 2 diabetes mellitus in the United States.
    Li Q; Chitnis A; Hammer M; Langer J
    Diabetes Ther; 2014 Dec; 5(2):579-90. PubMed ID: 25256818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incretin therapy for type 2 diabetes in Spain: a cost-effectiveness analysis of liraglutide versus sitagliptin.
    Mezquita Raya P; Pérez A; Ramírez de Arellano A; Briones T; Hunt B; Valentine WJ
    Diabetes Ther; 2013 Dec; 4(2):417-30. PubMed ID: 24132613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United States.
    Wang B; Roth JA; Nguyen H; Felber E; Furnback W; Garrison LP
    PLoS One; 2015; 10(4):e0121915. PubMed ID: 25849542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin.
    Steen Carlsson K; Persson U
    J Med Econ; 2014 Sep; 17(9):658-69. PubMed ID: 24950434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.
    Smits MM; Tonneijck L; Muskiet MH; Kramer MH; Pouwels PJ; Pieters-van den Bos IC; Hoekstra T; Diamant M; van Raalte DH; Cahen DL
    Diabetologia; 2016 Dec; 59(12):2588-2593. PubMed ID: 27627981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of liraglutide in type II diabetes: a systematic review.
    Zueger PM; Schultz NM; Lee TA
    Pharmacoeconomics; 2014 Nov; 32(11):1079-91. PubMed ID: 25052903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain.
    Vidal J; Malkin SJP; Hunt B; Martín V; Hallén N; Javier Ortega F
    Diabetes Ther; 2020 Feb; 11(2):509-521. PubMed ID: 31925724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand.
    Deerochanawong C; Krittayaphong R; Romano JGU; Rhee NA; Permsuwan U
    Diabetes Ther; 2023 Mar; 14(3):531-552. PubMed ID: 36719606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients.
    Madsbad S
    Expert Rev Cardiovasc Ther; 2019 May; 17(5):377-387. PubMed ID: 31055989
    [No Abstract]   [Full Text] [Related]  

  • 17. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
    Pratley RE; Nauck M; Bailey T; Montanya E; Cuddihy R; Filetti S; Thomsen AB; Søndergaard RE; Davies M;
    Lancet; 2010 Apr; 375(9724):1447-56. PubMed ID: 20417856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke.
    Verma S; Poulter NR; Bhatt DL; Bain SC; Buse JB; Leiter LA; Nauck MA; Pratley RE; Zinman B; Ørsted DD; Monk Fries T; Rasmussen S; Marso SP
    Circulation; 2018 Dec; 138(25):2884-2894. PubMed ID: 30566004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective.
    Chuang LH; Verheggen BG; Charokopou M; Gibson D; Grandy S; Kartman B
    J Med Econ; 2016 Dec; 19(12):1127-1134. PubMed ID: 27310712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.